Leavell Investment Management Inc. Reduces Position in Baxter International Inc (NYSE:BAX)

Leavell Investment Management Inc. lessened its holdings in Baxter International Inc (NYSE:BAX) by 1.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 13,429 shares of the medical instruments supplier’s stock after selling 149 shares during the period. Leavell Investment Management Inc.’s holdings in Baxter International were worth $1,094,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also made changes to their positions in BAX. American Research & Management Co. acquired a new position in shares of Baxter International during the 1st quarter worth approximately $81,000. BKS Advisors LLC acquired a new position in Baxter International in the first quarter valued at approximately $207,000. Autus Asset Management LLC lifted its holdings in Baxter International by 5.4% in the first quarter. Autus Asset Management LLC now owns 101,597 shares of the medical instruments supplier’s stock valued at $8,260,000 after acquiring an additional 5,212 shares during the last quarter. TIAA FSB lifted its holdings in Baxter International by 18.9% in the first quarter. TIAA FSB now owns 18,766 shares of the medical instruments supplier’s stock valued at $1,526,000 after acquiring an additional 2,980 shares during the last quarter. Finally, Raymond James Trust N.A. lifted its holdings in Baxter International by 7.8% in the first quarter. Raymond James Trust N.A. now owns 15,431 shares of the medical instruments supplier’s stock valued at $1,255,000 after acquiring an additional 1,114 shares during the last quarter. Hedge funds and other institutional investors own 86.38% of the company’s stock.

Shares of BAX traded down $0.69 during mid-day trading on Thursday, hitting $76.00. 1,969,755 shares of the company’s stock were exchanged, compared to its average volume of 3,066,216. Baxter International Inc has a fifty-two week low of $61.05 and a fifty-two week high of $82.25. The company has a market capitalization of $38.45 billion, a price-to-earnings ratio of 24.92, a price-to-earnings-growth ratio of 1.82 and a beta of 0.96. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.50 and a current ratio of 2.09.

Baxter International (NYSE:BAX) last announced its earnings results on Thursday, April 25th. The medical instruments supplier reported $0.76 earnings per share for the quarter, topping the consensus estimate of $0.68 by $0.08. The business had revenue of $2.63 billion during the quarter, compared to the consensus estimate of $2.61 billion. Baxter International had a net margin of 14.27% and a return on equity of 19.50%. The business’s quarterly revenue was down 1.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.70 earnings per share. Equities research analysts forecast that Baxter International Inc will post 3.32 EPS for the current year.

The company also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Investors of record on Friday, June 7th will be issued a dividend of $0.22 per share. This is a boost from Baxter International’s previous quarterly dividend of $0.19. This represents a $0.88 annualized dividend and a yield of 1.16%. The ex-dividend date of this dividend is Thursday, June 6th. Baxter International’s dividend payout ratio is currently 24.92%.

BAX has been the topic of a number of research analyst reports. Wells Fargo & Co boosted their target price on Baxter International from $80.00 to $89.00 and gave the company an “outperform” rating in a research report on Wednesday, April 3rd. Zacks Investment Research lowered Baxter International from a “hold” rating to a “sell” rating in a research report on Tuesday, January 29th. Barclays raised Baxter International from an “underweight” rating to an “equal weight” rating and upped their price objective for the stock from $67.00 to $72.00 in a research report on Friday, February 1st. Piper Jaffray Companies reaffirmed an “overweight” rating and set a $80.00 price objective on shares of Baxter International in a research report on Friday, February 1st. Finally, Morgan Stanley upped their price objective on Baxter International from $80.00 to $83.00 and gave the stock an “overweight” rating in a research report on Tuesday, March 5th. Four equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company’s stock. Baxter International currently has an average rating of “Buy” and a consensus price target of $78.50.

In other news, Director Thomas T. Stallkamp sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, March 1st. The shares were sold at an average price of $75.16, for a total transaction of $75,160.00. Following the completion of the transaction, the director now directly owns 6,780 shares of the company’s stock, valued at approximately $509,584.80. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Peter S. Hellman sold 5,680 shares of the firm’s stock in a transaction that occurred on Monday, April 1st. The stock was sold at an average price of $81.89, for a total transaction of $465,135.20. Following the transaction, the director now directly owns 28,774 shares of the company’s stock, valued at $2,356,302.86. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 57,187 shares of company stock valued at $4,447,619. 0.70% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This story was first reported by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark & copyright laws. The original version of this story can be accessed at https://www.baseballdailydigest.com/news/2019/05/10/baxter-international-inc-bax-shares-sold-by-leavell-investment-management-inc.html.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products. The company operates through North and South America; Europe, Middle East and Africa; and Asia-Pacific segments. The company offers peritoneal dialysis and hemodialysis, and additional dialysis therapies and services; renal replacement therapies and other organ support therapies focused in the intensive care unit; sterile intravenous (IV) solutions, IV therapies, infusion pumps, administration sets, and drug reconstitution devices; and parenteral nutrition therapies.

Featured Story: How to trade on quiet period expirations

Institutional Ownership by Quarter for Baxter International (NYSE:BAX)

Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.